Vincent CORVEST, Senior Scientist & Business Manager at CALIXAR, will be pleased to present the poster “Toolbox For native Membrane Targets” during the Discovery On Target (DOT) event in Boston, from October 17 to 20, 2022. You will discover the CALIXAR fully native process to customize membrane proteins, look at our developing pipeline, and discuss your challenging targets to identify potential collaboration.
CALIXAR is a biotech company specialized in the identification and isolation of functional membrane therapeutic targets and antigens (GPCRs, Ion channels, Transporters, …). The company is currently investing in the extension of its pipeline of highly druggable membrane protein targets and native antigens. Within the next few years, CALIXAR will be able to offer to Pharma companies native and functional therapeutic targets validated and in a ready-to-discovery format.
The company wants to become a leader in the early discovery segment of drug development based on complex therapeutic targets (membrane proteins), a market predicted to be worth €70 bn by 2025
Meet Vincent during these 4 days of event to learn more on CALIXAR’s proprietary technology and exchange with him about your targets to secure the generation of new drugs, antibodies, or small molecules.
Discovery on Target (DOT) highlights advances in current and emerging “hot” targets and technologies, as well as target validation strategies for the discovery and development of novel therapeutic agents ranging from biologics to small molecules.
For more information: Discovery On Target 2022